November 16, 2026

To, **National Stock Exchange of India Limited**, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, **BSE Limited**, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	**Scrip Code: 532296**
ISIN: INE935A01035	**ISIN: INE935A01035**
Our Reference No. 71/26-27	**Our Reference No. 71/26-27**

Dear Sir/ Madam,

Sub: Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic of INLYTA® (axitinib) Tablets, 1 mg and 5 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark), today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA®1 (axitinib) tablets.

According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million*.

Kindly find attached media release which is self- explanatory.

Request you to take the same on record.

Thanking you.

For Glenmark Pharmaceuticals Limited

RASHMI KHANDELWAL
Digitally signed by RASHMI KHANDELWAL
Date: 2026.11.16 08:24:45 +05'30'

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839

Encl: As above

Press Release
For Immediate Distribution

Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic of INLYTA® (axitinib) Tablets, 1 mg and 5 mg

Elmwood Park, New Jersey, November 16, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark), today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA®[1] (axitinib) tablets.

According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million*.

"The launch of Axitinib Tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States," said **Marc Kikuchi, President & Business Head, North America**. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers."

[1]INLYTA® is a registered trademark of Pfizer Inc.

*IQVIA® National Sales Perspectives: Retail & Non-Retail, September 2026

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

Press Release
For Immediate Distribution

glenmark
A new way for a new world

For more information, please contact:

In the U.S.:	**In India:**
Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen, Nahigian Strategies danielle@nahigianstrategies.com	Akhila Natarajan mediarelations@glenmarkpharma.com Adfactors PR glenmark@adfactorspr.com